var data={"title":"Insulin regular: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Insulin regular: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/159801?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=insulin-regular-drug-information\" class=\"drug drug_general\">see &quot;Insulin regular: Drug information&quot;</a> and <a href=\"topic.htm?path=insulin-regular-patient-drug-information\" class=\"drug drug_patient\">see &quot;Insulin regular: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50707944\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Insulin Pen Safety Alert</span>\n      <span class=\"collapsible-date\">October 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Institute for Safe Medication Practices (ISMP) National Medication Errors Reporting Program (MERP) has issued a safety alert regarding reports of patients incorrectly using insulin pens at home, resulting in severe cases of hyperglycemia. Patients were not removing the inner cover of a standard insulin pen needle prior to attempting to administer the insulin, and thus were not receiving insulin doses.</p>\n        <p style=\"text-indent:0em;\">Health care professionals should instruct patients on the proper use of insulin pens and require patient demonstration to verify understanding. They should also verify which pen needles patients will be using at home, either standard pens or pens with automatic needle retraction devices, and tailor instruction accordingly.</p>\n        <p style=\"text-indent:0em;\">More information can be found at http://www.ismp.org/NAN/files/NAN-20171012.pdf.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2105104\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>HumuLIN R U-500 (CONCENTRATED);</li>\n      <li>HumuLIN R U-500 KwikPen;</li>\n      <li>HumuLIN R [OTC];</li>\n      <li>NovoLIN R ReliOn [OTC];</li>\n      <li>NovoLIN R [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104962\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Entuzity KwikPen;</li>\n      <li>Humulin R;</li>\n      <li>Novolin ge Toronto</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2983813\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidiabetic Agent, Parenteral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hyperkalemia, Adjunctive Treatment Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Insulin, Short-Acting</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443748\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperglycemia:</b> Limited data available (Cloherty 2012): <b>Note:</b> Neonates are extremely sensitive to the effects of insulin; initiate therapy at the lower end of infusion rate and monitor closely; routine use in neonates is not recommended: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">  Intermittent IV infusion: 0.05 to 0.1 units/kg infused over 15 minutes every 4 to 6 hours as needed; <b>Note:</b> Should be used as initial management; monitor blood glucose every 30 minutes to 1 hour following doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: Initial rate: 0.05 units/kg/<b>hour</b>, monitor blood glucose every 30 minutes and titrate in 0.01 units/kg/<b>hour</b> increments, usual range: 0.01 to 0.2 units/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperkalemia:</b> Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 0.1 units/kg with 400 mg/kg of glucose; <b>Note:</b> Ratio of 1 unit of insulin for every 4 g of glucose (Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: Initial bolus: 0.05 units/kg with 2 <b>mL</b>/kg of D<sub>10</sub>W followed by continuous IV infusion of insulin at 0.1 unit/kg/<b>hour</b> in combination with D<sub>10</sub>W infusion at 2 to 4 <b>mL</b>/kg/hour (Cloherty 2012); insulin infusions as low as 0.05 units/kg/<b>hour</b> in conjunction with dextrose infusion have been used in premature neonates (GA: &lt;28 weeks) (Malone 1991). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2983824\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=insulin-regular-drug-information\" class=\"drug drug_general\">see &quot;Insulin regular: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">The general objective of insulin replacement therapy is to approximate the physiologic pattern of insulin secretion. This requires a basal level of insulin throughout the day, supplemented by additional insulin at mealtimes. Since combinations using different types of insulins are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. The frequency of doses and monitoring must be individualized in consideration of the patient's ability to manage therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Type 1 diabetes mellitus:</b> Infants (Limited data available), Children, and Adolescents: <b>Note:</b> Insulin regimens should be individualized to achieve glycemic goals without causing hypoglycemia. Multiple daily doses or continuous subcutaneous infusion guided by blood glucose monitoring are the standard of diabetes care. The daily doses presented are expressed as the total units/kg/day <b>of all insulin formulations combined</b>. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial dose:</i> SubQ: 0.2 to 0.6 units/kg/day in divided doses. Conservative initial doses of 0.2 to 0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Division of daily insulin requirement (&quot;conventional therapy&quot;):</i> Generally, 50% to 75% of the daily insulin dose is given as an intermediate- or long-acting form of insulin (in 1 to 2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form of insulin at the same time before breakfast and dinner. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Division of daily insulin requirement (&quot;intensive therapy&quot;):</i> Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of rapid- or very rapid-acting insulin formulations 3 or more times daily. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Adjustment of dose:</i> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Usual maintenance range:</i> 0.5 to 1 unit/kg/day in divided doses; doses must be individualized; however an estimate can be determined based on phase of diabetes and level of maturity (ISPAD [Danne 2014]) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Partial remission phase (Honeymoon phase): &lt;0.5 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Prepubertal children (not in partial remission): 0.7 to 1 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pubescent Children and Adolescents: During puberty, requirements may substantially increase to &gt;1.2 unit/kg/day and in some cases up to 2 units/kg/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous SubQ insulin infusion (insulin pump):</i> A combination of a &quot;basal&quot; continuous insulin infusion rate with preprogrammed, premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of longer acting insulin (eg, NPH). Divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same premeal regular insulin dosage may be used. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Type 2 diabetes mellitus:</b> Children &ge;10 years and Adolescents: SubQ: The goal of therapy is to achieve an HbA<sub>1c</sub> &lt;6.5% as quickly as possible using the safe titration of medications. Initial therapy in metabolically unstable patients (eg, plasma glucose &ge; 250 mg/dL, HbA<sub>1c</sub> &gt;9% and symptoms excluding acidosis) may include once daily intermediate-acting insulin or basal insulin in combination with lifestyle changes and metformin. In patients who fail to achieve glycemic goals with metformin and basal insulin, may consider initiating prandial insulin (regular insulin or rapid acting insulin) and titrate to achieve goals. Once initial goal reached, insulin should be slowly tapered and the patient transitioned to lowest effective doses or metformin monotherapy if able (AAP [Copeland 2013]; ISPAD [Zeitler 2014]). <b>Note:</b> Patients who are ketotic or present with ketoacidosis require aggressive management as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetic ketoacidosis (DKA):</b> Limited data available: Infants, Children, and Adolescents: <b>Note:</b> Only IV regular insulin should be used for treatment of DKA; the rare exception where the use of SubQ rapid-acting insulin analogs (eg, aspart, lispro) may be appropriate is for patients with uncomplicated DKA in whom peripheral circulation is adequate and continuous IV regular insulin administration is not possible. Treatment should continue until resolution of acid-base abnormalities (eg, pH &gt;7.3, serum HCO3 &gt;15 mEq/L, and/or closure of anion gap); serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. As part of overall DKA management, dextrose should be added to IV fluids to prevent hypoglycemia, usually once serum glucose is between 250 to 300 mg/dL but it may be required sooner if serum glucose has decreased precipitously. Generally, only dextrose 5% is necessary and is added to NS or <sup>1</sup>/<sub>2</sub>NS; however, dextrose 10% or 12.5% may be necessary in some cases (ADA [Wolfsdorf 2006]; ISPAD [Wolfsdorf 2014]). Refer to institution-specific protocols where appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Initial:</i> 0.05 to 0.1 units/kg/<b>hour</b>; continue the rate at 0.05 to 0.1 units/kg/hour if tolerated until resolution of ketoacidosis (pH &gt;7.3; bicarbonate &gt;15 mEq/L and/or closure of anion gap); <b>Note:</b> Some patients (eg, some young children with DKA, or older children with established diabetes) may have marked sensitivity to insulin requiring lower infusion rates; these lower infusion rates should only be used provided that resolution of the acidosis continues (ADA [Wolfsdorf 2006]; ISPAD [Wolfsdorf 2014]). </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>After resolution of DKA:</i> Once ketoacidosis has resolved and oral intake is tolerated, transition to a SubQ insulin regimen. An overlap between discontinuation of IV insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels; timing of SubQ insulin administration prior to infusion discontinuation is dependent on type of insulin used; for SubQ regular insulin: 1 to 2 hours, or for rapid-acting insulin: 15 to 30 minutes (IPSAD [Wolfsdorf 2014]). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperkalemia:</b> Limited data available: Infants, Children, and Adolescents: IV: 0.1 unit/kg with 400 mg/kg of glucose; usual ratio of combination therapy of insulin to glucose is 1 unit of insulin for every 4 g of glucose (Hegenbarth 2008). An alternate approach is glucose 1 g/kg followed by 0.2 units of insulin/g of glucose administered over 15 to 30 minutes then infused continuously as a similar amount per hour (Fuhrman 2011). In adults, the usual dose is 10 units of insulin mixed with 25 g of dextrose (50 mL of D<sub>50</sub>W) administered over 15 to 30 minutes (ACLS [Vanden Hoek 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperosmolar hyperglycemic state (HHS):</b> Limited data available: Children and Adolescents: <b>Note:</b> Only regular IV insulin should be used. Insulin administration should be initiated when serum glucose concentration is no longer declining at a rate &ge;50 mg/dL per hour with &#64258;uid administration alone; earlier initiation may be required in patients with severe ketosis and acidosis. Infusion should continue until reversal of mental status changes and hyperosmolality. Serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. Refer to institution-specific protocols where appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Initial: 0.025 to 0.05 units/kg/<b>hour</b>; titrate dose to achieve a decrease in serum glucose concentration at a rate of 50 to 75 mg/dL per hour; higher rates of decline may be required in some patients; however, if rate of decline exceeds 100 mg/dL per hour discontinue infusion (ISPAD [Wolfsdorf 2014]; Zeitler 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetes mellitus:</b> SubQ: <b>Note:</b> Insulin requirements vary dramatically between patients and therapy requires dosage adjustments with careful medical supervision. Specific formulations may require distinct administration procedures; please see individual agents.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Diabetes mellitus, type 1:</i></b>\n      <b> Note:</b> Multiple daily injections (MDI) guided by blood glucose monitoring or the use of continuous subcutaneous insulin infusions (CSII) is the standard of care for patients with type 1 diabetes. Combinations of insulin formulations are commonly used.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Initial dose:</i> 0.5 to 1 units/kg/day in divided doses. Conservative initial doses of 0.2 to 0.4 units/kg/day may be recommended to avoid the potential for hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Division of daily insulin requirement:</i> Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate or long-acting form of insulin (in 1 to 2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting or short-acting form of insulin.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Adjustment of dose:</i> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain preprandial plasma glucose between 70 to 130 mg/dL for most patients. Since treatment regimens often consist of multiple formulations, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Usual maintenance range:</i> 0.5 to 1.2 units/kg/day in divided doses. Insulin requirements are patient-specific and may vary based on age, body weight, and/or activity factors</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Diabetes mellitus, type 2:</i></b> The goal of therapy is to achieve an HbA<sub>1c</sub> &lt;7% as quickly as possible using the safe titration of medications. According to a consensus statement by the ADA and European Association for the Study of Diabetes (EASD), basal insulin therapy (eg, intermediate- or long-acting insulin) should be considered in patients with type 2 diabetes who fail to achieve glycemic goals with lifestyle interventions and metformin &plusmn; a sulfonylurea. Pioglitazone or a GLP-1 agonist may also be considered prior to initiation of basal insulin therapy. In patients who continue to fail to achieve glycemic goals despite the addition of basal insulin, intensification of insulin therapy should be considered; this generally consists of multiple daily injections with a combination of insulin formulations (Nathan 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Intensification of therapy:</i> Add a second injection of a short-, rapid-, or intermediate-acting insulin as needed based on blood glucose monitoring; the timing of administration and type of insulin added for intensification of therapy depends on the blood glucose level that is consistently out of the target range (eg, preprandial glucose levels before lunch or dinner, postprandial glucose levels, and/or bedtime glucose levels). Additional injections and subsequent dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Intensification of therapy can usually begin with a second injection of ~4 units/day followed by adjustments of ~2 units/day every 3 days until the targeted blood glucose is within range (Nathan 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">In the setting of glucose toxicity (loss of beta-cell sensitivity to glucose concentrations), insulin therapy may be used for short-term management to restore sensitivity of beta-cells; in these cases, the dose may need to be rapidly reduced/withdrawn when sensitivity is reestablished.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Insulin requirements are reduced due to changes in insulin clearance or metabolism; there are no dosage adjustments provided in manufacturer's labeling; however, the following adjustments have been used by some clinicians (Aronoff 2007): Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute: No adjustment necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 50 mL/minute: Administer at 75% of normal dose and monitor glucose closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: Administer at 50% of normal dose and monitor glucose closely. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Because of a large molecular weight (6,000 daltons), insulin is not significantly removed by hemodialysis; supplemental dose is not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis: Because of a large molecular weight (6,000 daltons), insulin is not significantly removed by peritoneal dialysis; supplemental dose is not necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy: Administer at 75% of normal dose and monitor glucose closely; supplemental dose is not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104923\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HumuLIN R: 100 units/mL (3 mL, 10 mL) [contains metacresol, phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NovoLIN R: 100 units/mL (10 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NovoLIN R ReliOn: 100 units/mL (10 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HumuLIN R U-500 (CONCENTRATED): 500 units/mL (20 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Pen-injector, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HumuLIN R U-500 KwikPen: 500 units/mL (3 mL) [contains metacresol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104963\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2983825\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Do not use if solution is viscous or cloudy; use only if clear and colorless.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Administer 30 to 60 minutes before meals. Cold injections should be avoided. Administration is usually made into the subcutaneous fat of the thighs, arms, buttocks, or abdomen, with sites rotated. When mixing regular insulin with other insulin preparations, regular insulin should be drawn into the syringe first. While not preferred, regular insulin may be infused SubQ by external insulin pump (eg, when rapid-acting insulin not available) (Danne [ISPAD], 2014); however, when used in an external pump, it is not recommended to be diluted with other solutions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Concentrated preparation: U-500 formulation: Do not dilute or mix U-500 regular insulin. <b>U</b><b>-500 regular insulin vials are to be used only in conjunction with a dedicated U-500 insulin syringe; dosage conversion is not required with the U-500 syringe</b>. Only in cases where the U-500 insulin syringe is not available, a U-100 insulin syringe or a tuberculin syringe may be necessary.<b></b>When using a U-100 syringe or a tuberculin syringe to deliver Humulin R U-500 (from vial), a conversion step is required to ensure the correct amount of Humulin R U-500 is drawn up in the syringe. To avoid dosing errors when using a U-100 insulin syringe, the prescribed dose should be written in actual insulin units and as unit markings on the U-100 insulin syringe (eg, Humulin R U-500 50 units = 10 units on a U-100 insulin syringe). To avoid dosing errors when using a tuberculin syringe, the prescribed dose should be written in actual insulin units and as a volume (eg, Humulin R U-500 50 units = 0.1 mL on a tuberculin syringe). Do not perform dose conversions when using the KwikPen; the dose window shows the number of units to be injected. Do not transfer KwikPen insulin into a syringe for administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: May be administered IM in selected clinical situations; close monitoring of blood glucose and serum potassium as well as medical supervision is required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Regular U-100 insulin is the preferred insulin formulation approved for IV administration; requires close monitoring of blood glucose and serum potassium; appropriate medical supervision. If possible, do not administer mixtures of insulin formulations intravenously. IV administration of U-500 regular insulin is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV Infusion: Insulin loss will occur by adsorption to plastic (ie, PVC, polyethylene, polyolefin, polypropylene) IV containers and tubing (Greenwood 2012; Hirsch 1977; Hirsch 1981; Rocchio 2013; Thompson 2012). To minimize insulin adsorption to plastic (eg, PVC, polyethylene polyolefin, polypropylene) IV tubing: Prior to administration, flush IV tubing with a priming volume of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (Goldberg 2006; Jacobi 2012; Thompson 2012). Studies examining this issue in neonates suggest that flushing the IV tubing prior to administration reduces adsorption and provides improved and more predictable insulin delivery; however, the combination of flushing along with preconditioning (waiting a predefined time after flushing the IV line before infusing) provides the greatest reduction in insulin adsorption; wait times for preconditioning varied among studies from 20 to 60 minutes; flush volumes varied and were as high as 20 mL (Fuloria 1998; Hewson 2000; Simeon 1994). Refer to institution-specific protocols where appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If insulin is required prior to the availability of the insulin drip, regular insulin should be administered by IV push injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Because of adsorption to plastic IV tubing or infusion bags, the actual amount of insulin being administered could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on the effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SubQ dosing regimen (Moghissi 2009); however, the transition to SubQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SubQ insulin should be given 1 to 4 hours prior to the discontinuation of IV insulin to prevent hyperglycemia (Moghissi 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472662\" class=\"block uicn drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV Infusion:</b> 0.1 unit/mL <b>or</b> 0.5 unit/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472661\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 0.1 unit/mL, 0.5 unit/mL, <b>or</b> 1 unit/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2105118\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Humulin R U-100: Store unopened vials in refrigerator between 2&deg;C and 8&deg;C (36&deg;F to 46&deg;F); do not freeze; keep away from heat and sunlight. Once punctured (in use), vials may be stored for up to 31 days in the refrigerator between 2&deg;C and 8&deg;C (36&deg;F to 46&deg;F) or at room temperature of &le;30&deg;C (&le;86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Humulin R U-500:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vials: Store unopened vials (not in use) in a refrigerator (2&deg;C to 8&deg;C [36&deg;F to 46&deg;F]) until expiration date or may be stored at room temperature &lt;30&deg;C [86&deg;F]) for up to 40 days. Protect from heat and light; do not freeze and do not use if the vial has been frozen. Store vials currently opened (in use) in a refrigerator (2&deg;C to 8&deg;C [36&deg;F to 46&deg;F]) or at room temperature &lt;30&deg;C [86&deg;F]) and discard after 40 days. Do not shake vial.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">KwikPen: Store unopened pens (not in use) in a refrigerator (2&deg;C to 8&deg;C [36&deg;F to 46&deg;F]) until expiration date or may be stored at room temperature (&lt;30&deg;C [86&deg;F]) for up to 28 days. Protect from heat and light; do not freeze or use if pen has been frozen. Store in-use (opened) pens at room temperature (&lt;30&deg;C [86&deg;F]) and discard pen after 28 days; do not refrigerate. For single-patient use only.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Novolin R: Store unopened vials in refrigerator between 2&deg;C and 8&deg;C (36&deg;F to 46&deg;F) until product expiration date or at room temperature &le;25&deg;C (&le;77&deg;F) for up to 42 days; do not freeze; keep away from heat and sunlight. Once punctured (in use), store vials at room temperature &le;25&deg;C (&le;77&deg;F) for up to 42 days (this includes any days stored at room temperature prior to opening vial); refrigeration of in-use vials is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canadian labeling (not in US labeling): All products: Unopened vials, cartridges, and pens should be stored under refrigeration between 2&deg;C and 8&deg;C (36&deg;F to 46&deg;F) until the expiration date; do not freeze; keep away from heat and sunlight. Once punctured (in use), Humulin vials, cartridges, and pens should be stored at room temperature &lt;25&deg;C (&lt;77&deg;F) for up to 4 weeks. Once punctured (in use), Novolin ge vials, cartridges, and pens may be stored for up to 1 month at room temperature &lt;25&deg;C (&lt;77&deg;F) for vials or &lt;30&deg;C (&lt;86&deg;F) for pens/cartridges; do not refrigerate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>For SubQ administration:</b> <i>Humulin R U-100:</i> According to the manufacturer, insulin diluted with the manufacturer&rsquo;s sterile diluent in a glass vial may be stored at 30&deg;C (86&deg;F) for up to 14 days or at 5&deg;C (41&deg;F) for up to 28 days. Do not store diluted insulin in a plastic syringe. Store unused sterile diluent at room temperature; once in-use, the sterile diluent vial should be used within 28 days (data on file [Eli Lilly 2018]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>For IV infusion:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Humulin R U-100:</i> Stable for 48 hours at room temperature or for 48 hours under refrigeration followed by 48 hours at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Novolin R:</i> Stable for 24 hours at room temperature</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> After dilution of 100 units of regular human insulin (product not specified) in 100 mL of 0.9% NaCl (PVC bag), the solution is stable under refrigeration between 2&deg;C and 8&deg;C (36&deg;F to 46&deg;F) for up to 336 hours (Rocchio 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2983814\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of diabetes mellitus (type 1 or type 2) to improve glycemic control (FDA approved in children and adults); has also been used for treatment of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) and treatment of hyperkalemia (used in combination with glucose to cause intracellular shift of potassium and lower serum potassium levels)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104961\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">HumuLIN R may be confused with HumaLOG, Humira, HumuLIN 70/30, HumuLIN N, NovoLIN 70/30, NovoLIN R, NovoLOG</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">NovoLIN R may be confused with HumuLIN R, NovoLIN 70/30, NovoLIN N, NovoLOG</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Insulin may be confused with influenza virus vaccine. Medication errors have occurred when insulin was inadvertently administered instead of influenza virus vaccine. These products are refrigerated and may be stored in close proximity to each other.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. <b><i>Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.</i></b></p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Insulin (short- or rapid-acting insulin products used for sliding scale) is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to higher risk of hypoglycemia associated with sliding scale insulin without improvements in hyperglycemia, regardless of care setting. Recommendation pertains to the sole use of short- or rapid-acting insulins in the absence of basal or long-acting insulin; recommendation does not apply to the titration of basal insulin or the use of additional short- or rapid-acting insulin in conjunction with scheduled insulin (ie, correction insulin) (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Concentrated solutions (eg, U-500) should not be available in patient care areas. U-500 regular insulin should be stored, dispensed, and administered separately from U-100 regular insulin. U-500 insulin vials are to be used in conjunction only with a dedicated U-500 insulin syringe. Though no longer recommended by the manufacturer, in cases where the U-500 insulin syringe is not available, a U-100 insulin syringe or a tuberculin syringe may be used (conversion step required to ensure correct dose is drawn up). For patients who receive U-500 insulin in the hospital setting, highlighting the strength prominently on the patient&rsquo;s medical chart and medication record may help to reduce dispensing errors. For patients being discharged from the hospital and/or in the outpatient setting, a U-500 insulin syringe is available by prescription only and should be prescribed/dispensed in conjunction with U-500 insulin vials.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104971\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Erythema at injection site, injection site pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hypoglycemia, hypokalemia, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, hypersensitivity, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Hypertrophy at injection site, lipoatrophy at injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104968\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to regular insulin or any component of the formulation; during episodes of hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for insulin is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2105113\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe, life-threatening, generalized allergic reactions, including anaphylaxis, may occur. If hypersensitivity reactions occur, discontinue therapy, treat the patient with supportive care and monitor until signs and symptoms resolve.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from changes in meal pattern (eg, macronutrient content, timing of meals), changes in the level of physical activity, increased work or exercise without eating, or changes to coadministered medications. Use of long-acting insulin preparations (eg, insulin degludec, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Patients with renal or hepatic impairment may be at a higher risk. Symptoms differ in patients and may change over time in the same patient; awareness may be less pronounced in those with long standing diabetes, diabetic nerve disease, patients taking beta-blockers, or in those who experience recurrent hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium frequently with IV insulin use and supplement potassium when necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac disease: Concurrent use with peroxisome proliferator-activated receptor (PPAR)-gamma agonists, including thiazolidinediones (TZDs) may cause dose-related fluid retention and lead to or exacerbate heart failure, particularly when used in combination with insulin. If PPAR-gamma agonists are prescribed, monitor for signs and symptoms of heart failure. If heart failure develops, consider PPAR-gamma agonist dosage reduction or therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; increased risk of hypoglycemia. Dosage requirements may be reduced and patients may require more frequent dose adjustment and glucose monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; increased risk of hypoglycemia. Dosage requirements may be reduced and patients may require more frequent dose adjustment and glucose monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hospitalized patients with diabetes: Exclusive use of a sliding scale insulin regimen in the inpatient hospital setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, <b>basal</b> insulin or <b>basal</b> plus bolus is preferred. In noncritically ill patients with adequate nutritional intake, a combination of <b>basal </b>insulin, nutritional, and correction components is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia. A blood glucose value &lt;70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia (ADA 2017d).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple-dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product variation: Human insulin differs from animal-source insulin. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; U-500 regular insulin: <b>U-500 regular insulin is a concentrated insulin formulation which contains 500 units of insulin per mL and is intended for subQ administration only;</b> <b>do not administer IV or IM or use in an insulin pump</b>. Prescribe only to patients who require more than 200 units of insulin per day. Doses from a U-500 regular insulin vial should be drawn up only with a dedicated U-500 insulin syringe. Do not mix or dilute U-500 regular insulin with other insulin formulations. Insulin U-500 also has a delayed onset and longer duration of action compared to regular insulin U-100, and has both prandial and basal properties (ADA 2017f). Do not perform dose conversions when using the KwikPen, the dose window shows the number of units to be injected. Do not transfer insulin from the KwikPen to a syringe for administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- or long-acting insulin via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IM administration: Regular insulin U-100 (ie, 100 units/mL) may be administered IM in selected clinical situations to control hyperglycemia (eg, DKA); close monitoring of blood glucose and serum potassium as well as medical supervision is required. Do not administer U-500 regular insulin IM.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: Regular insulin U-100 (ie, 100 units/mL) may be administered IV in selected clinical situations (eg, DKA, hyperkalemia); close monitoring of blood glucose and serum potassium as well as medical supervision is required. Do not administer U-500 regular insulin IV.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104975\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104974\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12880&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the hypoglycemic effect of Insulins.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edetate Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving  both basal insulin and a sulfonylurea.<b> Exceptions: </b>Liraglutide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: If liraglutide is used for the treatment of diabetes (Victoza), consider insulin dose reductions. The combination of liraglutide and insulin should be avoided if liraglutide is used exclusively for weight loss (Saxenda).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, dose reductions should be considered to reduce the risk of hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14079518\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2105111\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Animal reproduction studies have not been conducted. Exogenous insulin bound to anti-insulin antibodies can be detected in cord blood (Menon 1990).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2018c; Blumer 2013; Lambert 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28 to 32 weeks' gestation. Following delivery, insulin requirements decrease rapidly (ACOG 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Insulin therapy is the preferred treatment of type 1 and type 2 diabetes in pregnant women, as well as GDM when pharmacologic therapy is needed (ACOG 190 2018; ADA 2018c). Rapid acting insulins may be preferred over regular human insulin in women trying to conceive (Blumer 2013); however, there is no need to switch a pregnant woman who is well-controlled on injectable human insulin to a short acting analogue (Lambert 2013). Regular insulin is used intravenously for glycemic control during labor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2983826\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diabetes: Plasma glucose, electrolytes, HbA<sub>1c</sub></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">DKA/HHS: Vital signs, arterial blood gases (initial), venous pH, CBC with differential, urinalysis, serum glucose BUN, creatinine, electrolytes, calcium, magnesium, phosphate, anion gap, fluid status blood &beta;-hydroxybutyrate (&beta;-OH) concentration; neurological observations; mental status (ISPAD [Wolfsdorf 2014]). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperkalemia: Serum potassium and glucose must be closely monitored to avoid hypoglycemia and/or hypokalemia. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2983827\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma Blood Glucose and HbA<sub>1c</sub> Goals for Diabetes Patients (ADA 2016): <b>Note:</b> Goals should be individualized based on individual needs/circumstances (eg, patients who experience severe hypoglycemia, patients with hypoglycemic unawareness); lower goals may be reasonable if they can be achieved without excessive hypoglycemia. <b>Note:</b> Postprandial blood glucose should be measured when there is a discrepancy between preprandial blood glucose concentrations and HbA<sub>1c</sub> values and to help assess glycemia for patients who receive basal/bolus regimens. It is usually drawn 1 to 2 hours after starting a meal and is considered to be the &quot;peak.&quot;</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial glucose: 90 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime/overnight glucose: 90 to 150 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults, nonpregnant:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Postprandial glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104981\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either <i>E. coli</i> or <i>Saccharomyces cerevisiae</i>. Regular insulin has an identical structure to that of native human insulin. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin regular is a short-acting insulin analog.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104982\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Onset and duration of hypoglycemic effects depend upon the route of administration (absorption and onset of action are more rapid after deeper IM injections than after SubQ), site of injection (onset and duration are progressively slower with SubQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered. Rate of absorption, onset, and duration of activity may be affected by exercise, presence of lipodystrophy, local blood supply, and/or temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Onset of action: SubQ: 0.25 to 0.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: SubQ: U-100: 2.5 to 5 hours; U-500: 4 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: U-100: 2 to 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: U-100: 4 to 12 hours (may increase with dose); U-500: 13 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: IV, SubQ: V<sub>d</sub>: 0.26 to 0.36 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: 55% to 77%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: ~0.5 to 1 hour (dose-dependent); SubQ: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: SubQ: 0.8 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422171\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (HumuLIN R Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (3 mL): $53.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (HumuLIN R U-500 (CONCENTRATED) Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 units/mL (20 mL): $1,784.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (NovoLIN R Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (10 mL): $165.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (NovoLIN R ReliOn Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (10 mL): $165.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (HumuLIN R U-500 KwikPen Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 units/mL (3 mL): $344.52</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038885\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actrapid (DK, SG);</li>\n      <li>Glinux-R (MX);</li>\n      <li>Huminsulin Basal (CH);</li>\n      <li>Huminsulin Normal (AT);</li>\n      <li>Humulin (UA);</li>\n      <li>Humulin R (AE, AU, BB, BG, BH, BM, BZ, CL, CN, CO, CR, CY, CZ, DO, EE, EG, GT, GY, HK, HR, HU, ID, IL, IT, JO, KR, KW, LB, LI, LK, LT, LU, MX, MY, NI, NZ, PA, PE, PH, PK, PY, QA, RO, SA, SE, SI, SK, SR, SV, TH, TR, VN);</li>\n      <li>Humulin Regular (DK, FI, GR, PT, RU);</li>\n      <li>Humulin S (GB);</li>\n      <li>Humulina Regular (ES);</li>\n      <li>Humuline R (BE);</li>\n      <li>Iletin-R (IN);</li>\n      <li>Insolidd-R (ZW);</li>\n      <li>Insugen R (MY, TH);</li>\n      <li>Insugen-R (ZW);</li>\n      <li>Insuget R (PH);</li>\n      <li>Insulet R (BD);</li>\n      <li>Insulin Insulatard HM (CH);</li>\n      <li>Insulina Humulin R (AR);</li>\n      <li>Insuman (NO);</li>\n      <li>Insuman Basal (ET, IE, TZ, ZW);</li>\n      <li>Insuman R (CL);</li>\n      <li>Insuman Rapid (TH, ZW);</li>\n      <li>Jusline R (TZ);</li>\n      <li>Scilin R (PH);</li>\n      <li>Umuline Rapide (FR);</li>\n      <li>Winsulin-R (TH);</li>\n      <li>Wosulin R (BR, TZ)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins, &quot;Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational Diabetes Mellitus,&quot; <i>Obstet Gynecol</i>, 2005, 105(3):675-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Committee on Practice Bulletins--Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2013;122(2 Pt 1):406-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/23969827 /pubmed\" target=\"_blank\" id=\"23969827 \">23969827 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 12. Management of Diabetes in Pregnancy. <i>Diabetes Care</i>. 2016;39(suppl 1):S94-S98. doi:10.2337/dc16-S015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/26696688/pubmed\" target=\"_blank\" id=\"26696688\">26696688</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association. 13. Management of Diabetes in Pregnancy. <i>Diabetes Care</i>. 2017c;40(Suppl 1):S114-S119.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/27979900/pubmed\" target=\"_blank\" id=\"27979900\">27979900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). Standards of medical care in diabetes 2016. <i>Diabetes Care</i>. 2016;39(Suppl 1):S1-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/24357209 /pubmed\" target=\"_blank\" id=\"24357209 \">24357209 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/24194617 /pubmed\" target=\"_blank\" id=\"24194617 \">24194617 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href=\"http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html\" target=\"_blank\">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Copeland KC, Silverstein J, Moore KR, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. <i>Pediatrics</i>. 2013;131(2):364-382.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/23359574 /pubmed\" target=\"_blank\" id=\"23359574 \">23359574 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Danne T, Bangstad HJ, Deeb L, et al. ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Insulin treatment in children and adolescents with diabetes.<i> Pediatr Diabetes</i>. 2014;15(Suppl 20):115-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/25182312 /pubmed\" target=\"_blank\" id=\"25182312 \">25182312 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuloria M, Friedberg MA, DuRant RH, Aschner JL. Effect of flow rate and insulin priming on the recovery of insulin from microbore infusion tubing. <i>Pediatrics</i>. 1998;102(6):1401-1406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/9832576 /pubmed\" target=\"_blank\" id=\"9832576 \">9832576 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 4th ed. Elsevier Health; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldberg PA, Kedves A, Walter K, Groszmann A, Belous A, Inzucchi SE. &quot;Waste not, want not&quot;: determining the optimal priming volume for intravenous insulin infusions. <i>Diabetes Technol Ther</i>. 2006;8(5):598-601.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/17037974/pubmed\" target=\"_blank\" id=\"17037974\">17037974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenwood BC, Chesnick MA, Szumita PM, Belisle C, Cotugno M. Stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. <i>Hosp Pharm</i>. 2012;47(5):367-370.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo; <i>Pediatrics,</i> 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hewson M, Nawadra V, Oliver J, Odgers C, Plummer J, Simmer K. Insulin infusions in the neonatal unit: delivery variation due to adsorption. <i>J Paediatr Child Health</i>. 2000;36(3):216-220.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/10849219 /pubmed\" target=\"_blank\" id=\"10849219 \">10849219 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsch JI, Fratkin MJ, Wood JH, Thomas RB. Clinical signigicance of insulin adsorption by polyvinyl chloride infusion systems. <i>Am J Hosp Pharm</i>. 1977;34(6):583-588.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/406784 /pubmed\" target=\"_blank\" id=\"406784 \">406784 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humulin R (insulin regular) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humulin R U-500 (insulin regular concentrate) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsch JI, Wood JH, Thomas RB. Insulin adsorption to polyolefin infusion bottles and polyvinyl chloride administration sets. <i>Am J Hosp Pharm</i>. 1981;38(7):995-997.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/7020415 /pubmed\" target=\"_blank\" id=\"7020415 \">7020415 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP), &quot;Standard Concentrations of Neonatal Drug Infusions,&quot; <i>ISMP</i>, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobi J, Bircher N, Krinsley J, et al, &ldquo;Guidelines for the Use of an Insulin Infusion for the Management of Hyperglycemia in Critically Ill Patients,&rdquo; <i>Crit Care Med</i>, 2012, 40(12):3251-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/23164767/pubmed\" target=\"_blank\" id=\"23164767\">23164767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitzmiller JL, Block JM, Brown FM, et al, &quot;Managing Preexisting Diabetes for Pregnancy: Summary of Evidence and Consensus Recommendations for Care,&quot; <i>Diabetes Care</i>, 2008, 31(5):1060-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/18445730/pubmed\" target=\"_blank\" id=\"18445730\">18445730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambert K, Holt RI. The use of insulin analogues in pregnancy.<i> Diabetes Obes Metab</i>. 2013;15(10):888-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/23489521 /pubmed\" target=\"_blank\" id=\"23489521 \">23489521 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malone TA, &quot;Glucose and Insulin Versus Cation-Exchange Resin for the Treatment of Hyperkalemia in Very Low Birth Weight Infants,&quot; <i>J Pediatr</i>, 1991, 118(1):121-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/1986079/pubmed\" target=\"_blank\" id=\"1986079\">1986079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menon RK, Cohen RM, Sperling MA, et al, &quot;Transplacental Passage of Insulin in Pregnant Women With Insulin-Dependent Diabetes Mellitus. Its Role in Fetal Macrosomia,&quot; <i>N Engl J Med</i>, 1990, 323(5):309-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/2195347/pubmed\" target=\"_blank\" id=\"2195347\">2195347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al, &quot;Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus,&quot; <i>Diabetes Care</i>, 2007, 30(Suppl 2):251-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moghissi ES, Korytkowski MT, DiNardo M, et al, &ldquo;American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control,&rdquo; <i>Endocr Pract</i>, 2009, 15(4):353-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/19454396/pubmed\" target=\"_blank\" id=\"19454396\">19454396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nathan DM, &ldquo;Insulin Treatment in the Elderly Diabetic Patient,&rdquo; <i>Clin Geriatr Med</i>, 1990, 6(4):923-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/2224755/pubmed\" target=\"_blank\" id=\"2224755\">2224755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &quot;Standardizing I.V. Infusion Concentrations: National Survey Results,&quot; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/15461903 /pubmed\" target=\"_blank\" id=\"15461903 \">15461903 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rocchio MA, Belisle CD, Greenwood BC, Cotugno MC, Szumita PM. Evaluation of the maximum beyond-use-date stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. <i>Diabetes Metab Syndr Obes</i>. 2013;6:389-932.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/24143117 /pubmed\" target=\"_blank\" id=\"24143117 \">24143117 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simeon PS, Geffner ME, Levin SR, et al, &quot;Continuous Insulin Infusions in Neonates: Pharmacologic Availability of Insulin in Intravenous Solutions,&quot; <i> J Pediatr</i>, 1994, 124(5 Pt 1):818-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/8176576/pubmed\" target=\"_blank\" id=\"8176576\">8176576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson CD, Vital-Carona J, Faustino EV. The effect of tubing dwell time on insulin adsorption during intravenous insulin infusions. <i>Diabetes Technol Ther</i>.2012;14(10):912-916.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/22746979/pubmed\" target=\"_blank\" id=\"22746979\">22746979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):829-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. <i>Int J Endocrinol</i>. 2012;2012:296368.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/22500167 /pubmed\" target=\"_blank\" id=\"22500167 \">22500167 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolfsdorf J, Glaser N, Sperling MA, American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: a consensus statement from the American Diabetes Association. <i>Diabetes Care</i>. 2006;29(5):1150-1159.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/16644656 /pubmed\" target=\"_blank\" id=\"16644656 \">16644656 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolfsdorf JI, Allgrove J, Craig ME, et al. Diabetic ketoacidosis and hyperglycemic hyperosmolar state. ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. <i>Pediatr Diabetes</i>. 2014;15(Suppl 20):154-179.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/25041509 /pubmed\" target=\"_blank\" id=\"25041509 \">25041509 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeitler P, Fu J, Tandon N, et al. ISPAD. Type 2 diabetes in the child and adolescent. <i>Pediatr Diabetes</i>. 2014;15(Suppl 20): 26-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/25182306 /pubmed\" target=\"_blank\" id=\"25182306 \">25182306 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeitler P, Haqq A, Rosenbloom A, Glaser N. Drugs and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. <i>J Pediatr</i>. 2011;158(1):9-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/21035820 /pubmed\" target=\"_blank\" id=\"21035820 \">21035820 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12880 Version 157.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50707944\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2105104\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2104962\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F2983813\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443748\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F2983824\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2104923\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F2104963\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2983825\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Neonatal\" href=\"#F14472662\" class=\"outlineLink\">Usual Infusion Concentrations: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472661\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2105118\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2983814\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2104961\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2104971\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2104968\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2105113\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F2104975\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2104974\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F14079518\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2105111\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2983826\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F2983827\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2104981\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F2104982\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422171\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038885\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12880|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=insulin-regular-drug-information\" class=\"drug drug_general\">Insulin regular: Drug information</a></li><li><a href=\"topic.htm?path=insulin-regular-patient-drug-information\" class=\"drug drug_patient\">Insulin regular: Patient drug information \t</a></li></ul></div></div>","javascript":null}